Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-22T08:43:19.661Z Has data issue: false hasContentIssue false
  • English
  • Français

Alprazolam and Exposure Alone and Combined in Panic Disorder with Agoraphobia

A Controlled Study in London and Toronto

Published online by Cambridge University Press:  02 January 2018

Isaac M. Marks ,
Richard P. Swinson ,
Metin Başoǧlu ,
Klaus Kuch ,
Homa Noshirvani ,
Geraldine O'Sullivan ,
Paul T. Lelliott ,
Marlene Kirby ,
Gary McNamee  and
Seda Sengun
...Show all authors
Isaac M. Marks*
Affiliation:
Institute of Psychiatry and Bethlem-Maudsley Hospital, London SE5 8AF
Richard P. Swinson
Affiliation:
Toronto General Hospital and University of Toronto, Canada
Metin Başoǧlu
Affiliation:
Institute of Psychiatry, London
Klaus Kuch
Affiliation:
Toronto General Hospital and University of Toronto
Homa Noshirvani
Affiliation:
Institute of Psychiatry, London
Geraldine O'Sullivan
Affiliation:
Institute of Psychiatry, London
Paul T. Lelliott
Affiliation:
Institute of Psychiatry, London
Marlene Kirby
Affiliation:
Toronto General Hospital and University of Toronto
Gary McNamee
Affiliation:
Institute of Psychiatry, London
Seda Sengun
Affiliation:
Institute of Psychiatry, London
Kim Wickwire
Affiliation:
Toronto General Hospital and University of Toronto
*
∗Correspondence
Get access Rights & Permissions [Opens in a new window]

Abstract

A cross-national randomised trial of alprazolam for chronic panic disorder with agoraphobia was run. Compared with previous trials it had three new features: an exposure therapy contrast group, a six-month treatment-free follow-up, and a low rate of early placebo drop-outs (‘non-evaluables’). The dose of alprazolam was high (5 mg/day). The 154 patients had eight weeks of: alprazolam and exposure (combined treatment); or alprazolam and relaxation (a psychological placebo); or placebo and exposure; or placebo and relaxation (double placebo). Drug taper was from weeks 8 to 16. Follow-up was to week 43. Results were similar at both sites. Treatment integrity was good. All four treatment groups, including double placebo, improved well on panic throughout. On non-panic measures, by the end of treatment, both alprazolam and exposure were effective, but exposure had twice the effect size of alprazolam. During taper and follow-up, gains after alprazolam were lost, while gains after exposure were maintained. Combining alprazolam with exposure marginally enhanced gains during treatment, but impaired improvement thereafter. The new features put previous trials in a fresh light. By the end of treatment, though gains on alprazolam were largely as in previous studies, on phobias and disability they were half those with exposure. Relapse was usual after alprazolam was stopped, whereas gains persisted to six-month follow-up after exposure ceased. Panic improved as much with placebo as with alprazolam or exposure.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 162 , Issue 6 , June 1993 , pp. 776 - 787
Copyright
Copyright © The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alkubaisy, T., Marks, I. M., Logsoail, S., et al (1992) The role of exposure homework in phobia reduction: A controlled study. Behavior Therapy, 23, 599–621.CrossRefGoogle Scholar
Andersch, S., Rosenberg, N. K., Kullinsjö, H., et at (1991) Efficacy and safety of alprazolam, imipramine and placebo in the treatment of panic disorder: a Scandinavian multicenter study. Acta Psychiatrica Scandinavica, (suppl. 365), 18–27.CrossRefGoogle Scholar
Ballenger, J. C., Burrows, G. D., Dupont, R. L., et al (1988) Alprazolam in panic disorder and agoraphobia: results from a multicenter trial: I. Efficacy in short-term treatment. Archives of General Psychiatry, 45, 413–422.CrossRefGoogle ScholarPubMed
Başoǧlu, M., Lax, T., Kasvikis, Y., et al (1988) Patterns and predictors of improvement in obsessive compulsive disorder. Journal of Anxiety Disorders, 2, 299–317.CrossRefGoogle Scholar
Başoǧlu, M., Marks, I. M., Kilic, C., et al (1993a) The relationship between panic, anticipatory anxiety, agoraphobia, and global involvement in panic disorders with agoraphobia treated with alprazolam and exposure. (Submitted for publication.) CrossRefGoogle Scholar
Başoǧlu, M., Marks, I. M., Kilic, C., et al (1993b) Alprazolam and exposure for panic disorder with agoraphobia: attribution of improvement to medication predicts subsequent relapse. (Submitted for publication.) Google Scholar
Baxter, L., Schwartz, J. R., Bergman, K. S., et al (1992) PET scan changes after successful drug and behavioral treatment. Archives of General Psychiatry, 49, 681–689.CrossRefGoogle Scholar
Beck, A. T., Ward, C. H., Mendelson, M., et al (1961) An inventory of measuring depression. Archives of General Psychiatry, 4, 561–571.CrossRefGoogle ScholarPubMed
Bixler, E. O., Kales, A., Manfredi, R. L., et al (1991) Next-day memory impairment with triazolam use. Lancet, 337, 827–831.CrossRefGoogle ScholarPubMed
Bouton, M. E., Kenney, F. A. & Rosengard, C. (1990) State-dependent fear extinction with two benzodiazepine tranquilizers. Behavioral Neuroscience, 104, 44–55.CrossRefGoogle ScholarPubMed
Brown, J. L. & Hague, K. J. (1986) A review of alprazolam withdrawal. Drug Intelligence and Clinical Pharmacology, 20, 837–841.CrossRefGoogle Scholar
Chouinard, G., Annable, L., Fontaine, R., et al (1982) Alprazolam in the treatment of GAD and panic disorders: a double-blind placebo-controlled study. Psychopharmacology, 77, 229–233.CrossRefGoogle Scholar
Cross-National Collaborative Panic Study, Second Phase Investigators (CNCPS, SPI) (1992) Drug treatment of panic disorders. Comparative efficacy of alprazolam, imipramine and placebo. British Journal of Psychiatry, 160, 191–202.CrossRefGoogle Scholar
Derogatis, L. R., Lipman, R. S. & Covi, L. (1973) An out-patient psychiatric rating scale: preliminary report. Psychopharmaco-logical Bulletin, 9, 13–28.Google Scholar
Dunner, D. L., Ishiki, D., Avery, D. H., et al (1986) Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study. Journal of Clinical Psychiatry, 47, 458–460.Google ScholarPubMed
Echeburúa, E., Decorral, P. & Bajos, E. G. (1993) Self-exposure and alprazolam in the treatment of agoraphobia without current panic. Behavioural Psychotherapy (in press).CrossRefGoogle Scholar
Fiegenbaum, W. (1988) Long-term efficacy of ungraded versus graded massed exposure in agoraphobia. Panic and Phobias 2 (eds Hand, I. & Wittchen, H.-U.), pp. 83–88. New York: Springer-Verlag.CrossRefGoogle Scholar
Fyer, A. J., Liebowitz, M. R., Gorman, J. M., et al (1987) Discontinuation of alprazolam in panic patients. American Journal of Psychiatry, 144, 303–308.Google ScholarPubMed
Gelder, M. G. & Marks, I. M. (1966) Severe agoraphobia: a controlled trial. British Journal of Psychiatry, 112, 309–319.CrossRefGoogle Scholar
Ghosh, A. & Marks, I. M. (1987) Self-treatment of agoraphobia by exposure. Behavior Therapy, 18, 3–16.CrossRefGoogle Scholar
Gray, J. A. (1987) Interactions between drugs and behavior therapy. Theoretical Foundations of Behavior Therapy (eds Eysenck, H. J. & Martin, I.), pp. 433–447. New York: Plenum.CrossRefGoogle Scholar
Hamilton, M. (1959) The assessment of anxiety states by rating. British Journal of Medical Psychology, 32, 50–55.CrossRefGoogle ScholarPubMed
Hamilton, M. (1960) A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 56–62.CrossRefGoogle ScholarPubMed
Kellner, C. H. & Uhde, T. W. (1988) CT scanning in panic disorders. Abstract No. 37A. APA Abstracts, Montreal, May 10. Washington, DC: APA.Google Scholar
Klosko, J. S., Barlow, D. H., Tassinari, R. B., et al (1988) Alprazolam vs cognitive behaviour therapy in panic disorder: in Panic and Phobias 2 (eds Hand, I. & Wittchen, H. U.), pp. 54–65. New York: Springer-Verlag.CrossRefGoogle Scholar
Lader, M. H., Ron, M. & Petursson, H. (1984) Computed axial brain tomography on long-term benzodiazepine users. Psychological Medicine, 14, 203–206.CrossRefGoogle ScholarPubMed
Lavory, P. W., Keller, M. B. & Klerman, G. L. (1984) Relapse in affective disorders: reanalysis of the literature using life table methods. Journal of Psychiatric Research, 18, 13–25.CrossRefGoogle Scholar
Lelliott, P. T., Marks, I. M., Monteiro, W. O., et al (1987) Agoraphobics 5 years after imipramine and exposure: outcome and predictors. Journal of Nervous and Mental Disease, 175, 599–605.CrossRefGoogle ScholarPubMed
Lesser, I. M., Rubin, R. T., Pecknold, J. C., et al (1988) Secondary depression in panic disorder and agoraphobia. Archives of General Psychiatry, 45, 437–443.CrossRefGoogle ScholarPubMed
Maier, W., Roth, M., Argyle, N., et al (1991) Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder? European Archives of Psychiatry and Clinical Neurosciences, 241, 151–158.CrossRefGoogle ScholarPubMed
Marks, I. M. (1978) Living with Fear. New York: McGraw-Hill.Google Scholar
Marks, I. M. (1985) Psychiatric Nurse Therapists in Primary Care. Research Series. London: Royal College of Nursing.Google Scholar
Marks, I. M. (1986) Behavioural Psychotherapy: Maudsley Pocketbook of Management. Available from Prof. Marks, Institute of Psychiatry, London SE5 8AF.Google Scholar
Marks, I. M. (1987) Fears, Phobias and Rituals. New York: Oxford University Press.Google Scholar
Marks, I. M., Hallam, R. S., Philpott, R., et al (1977) Nursing in Behavioural Psychotherapy. London: Royal College of Nursing.Google Scholar
Marks, I. M. & Mathews, A. M. (1979) Brief standard self-rating for phobic patients. Behavior Research and Therapy, 17, 263–267.CrossRefGoogle ScholarPubMed
Marks, I. M., Gray, S., Cohen, S. D., et al (1983) Imipramine and brief therapist-aided exposure in agoraphobics having self-exposure homework: a controlled trial. Archives of General Psychiatry, 40, 153–162.CrossRefGoogle Scholar
Marks, I. M., Lelliott, P. T., Başoǧlu, M., et al (1988) Clomipramine and exposure for obsessive-compulsive disorder. British Journal of Psychiatry, 152, 522–534.CrossRefGoogle Scholar
Marks, I. M., Albuquerque, A., Cottraux, J., et al (1989) The ‘efficacy’ of alprazolam in panic disorder and agoraphobia: a critique of recent reports. Archives of General Psychiatry, 46, 668–669.Google ScholarPubMed
Marks, I. M., Greist, J., Başoǧlu, M., Noshirvani, H., et al (1992) Comment on the second phase of the Cross-National Panic Study. British Journal of Psychiatry, 160, 202–205.CrossRefGoogle Scholar
Mavissakalian, M. & Michelson, L. (1986) Agoraphobia: therapist-assisted in vivo exposure and imipramine. Journal of Clinical Psychiatry, 47, 117–122.Google ScholarPubMed
McDonald, R., Marks, I. M. & Blizard, R. (1988) Quality assurance of outcome in mental health care in clinical settings. Health Trends, 20, 111–114.Google ScholarPubMed
McNamee, G., O'Sullivan, G., Lelliott, P., et al (1989) Telephone-guided treatment for housebound agoraphobics with panic disorder: exposure vs relaxation. Behavior Therapy, 20, 491–497.CrossRefGoogle Scholar
Mellman, T. A. & Uhde, T. W. (1986) Withdrawal syndrome with gradual tapering of alprazolam. American Journal of Psychiatry, 143, 1464–1466.Google ScholarPubMed
Munjack, D. J., Crocker, B., Cabe, D., et al (1989) Alprazolam, propranolol and placebo in the treatment of panic disorder and agoraphobia with panic attacks. Journal of Clinical Psychopharmacology, 9, 22–27.CrossRefGoogle ScholarPubMed
O'Sullivan, G. & Marks, I. M. (1990) Long-term outcome of phobic and obsessive compulsive disorders after exposure: a review chapter. Handbook of Anxiety, Vol. 4 (eds Noyes, R., Roth, M. & Burrows, G.). Amsterdam: Elsevier.Google Scholar
O'Sullivan, G. & Marks, I. M., Başoǧlu, M., et al (1992) Side effects of alprazolam. (Submitted for publication.) Google Scholar
Pecknold, J. C., Swinson, R. P., Kuch, K., et al (1988) Alprazolam in panic disorder and agoraphobia: results from a multicenter trial: III. Discontinuation effects. Archives of General Psychiatry, 45, 429–436.CrossRefGoogle ScholarPubMed
Schmauss, C. & Krieg, J. C. (1987) Enlargement of CSF spaces in benzodiazepine abusers. Psychological Medicine, 17, 869–873.CrossRefGoogle ScholarPubMed
Sheehan, D. V., Raj, A. B., Harnett-Sheehan, K., et al (1990) Adinazolam sustained release in panic disorder: a pilot study. Irish Journal of Psychological Medicine, 7, 124–128.CrossRefGoogle Scholar
Spitzer, R. L., Williams, J. B. W. (1983) Structured Clinical Interview for DSM-III, Upjohn version (SCID-UP). Biometric Research Division, New York State Psychiatric Institute.Google Scholar
Tesar, G. E., Rosenbaum, J. F., Pollack, M. H., et al (1987) Clonazepam vs alprazolam in the treatment of panic disorder: interim analysis of a prospective, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry, 48 (suppl. 10).Google Scholar
Wolpe, J. & Lazarus, A. (1966) Behaviour Therapy Techniques. Oxford: Pergamon.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.